Table 1 Clinical and laboratory characteristics of the SS patients and HC subjects.
From: Role of mucosal-associated invariant T cells dynamics in pathogenesis of Sjögren syndrome
SS N = 23 | HC N = 23 | |
|---|---|---|
Age (years): median [min–max] | 45 [25–74] | 45 [25–75] |
Sex ratio (F/M) | 22/1 | 22/1 |
Tobacco exposure, n (%) | 1 (5) | – |
Alcohol chronic exposure, n (%) | 0 | – |
Clinical findings, n (%) | ||
Sicca syndrome | 23 (100) | – |
Oral dryness | 20 (87) | – |
Ocular dryness | 12 (52) | – |
Arthralgia | 6 (26) | – |
Peripheral nervous system involvement | 6 (26) | – |
Parotidomegaly | 3 (13) | – |
Skin rash | 1 (4) | – |
Pulmonary involvement | 1 (4) | – |
Lymph node involvement | 3 (13) | – |
Muscular involvement | 2 (9) | – |
Renal involvement | 0 | – |
Biological manifestation, n (%) | ||
Anti-SSA | 16 (70) | – |
Hypergammaglobulinemia | 11 (50) | – |
Anti-SSB | 7 (30) | – |
Lymphopenia | 5 (22) | – |
Positive rheumatoid factor | 6 (26) | – |
Complement consumption | 3 (15) | – |
Cryoglobulinemia | 3 (23) | – |
Pathological LSGB (focus score >/ = 1), n (%) | 14 (61) | – |
Grade 3 of Chisholm classification | 5 (22) | |
Grade 4 of Chisholm classification | 9 (39) | |
Past treatments, n (%) | ||
No | 9 (39) | |
HCQ | 9 (39) | – |
Corticosteroids | 8 (35) | – |
Methotrexate | 5 (22) | – |
Rituximab | 2 (9) | – |
Intravenous immunoglobulins | 2 (9) | – |
Rapamycin | 1 (4) | – |
Azathioprine | 1 (4) | – |
Current treatments, n (%) | ||
No | 12 (52) | – |
Hydroxychloroquine | 9 (39) | – |
Corticosteroids | 6 (26) | – |
Methotrexate | 1 (4) | – |
Associated other connective tissue diseases, n (%) | 6 (26%) | – |
